hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-03 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Vibrational spectroscopy, or infrared (IR) spectroscopy, allows for the identification of functional groups and, due to its low expense and robustness, is often used in teaching labs and the real-time monitoring of reaction progress in difficult to reach environments (high pressure, high temperature, gas phase, phase boundaries). Molecular vibrations are quantized in an analogous manner to electronic wavefunctions, with integer increases in frequency leading to higher energy states. The difference in energy between vibrational states is nearly constant, often falling in the energy range corresponding to infrared photons, because at normal temperatures molecular vibrations closely resemble harmonic oscillators. It allows for the crude identification of functional groups in organic molecules, but spectra are complicated by vibrational coupling between nearby functional groups in complex molecules. Therefore, its utility in structure determination is usually limited to simple molecules. Further complicating matters is that some vibrations do not induce a change in the molecular dipole moment and will not be observable with standard IR absorption spectroscopy. These can instead be probed through Raman spectroscopy, but this technique requires a more elaborate apparatus and is less commonly performed. However, as Raman spectroscopy relies on light scattering it can be performed on microscopic samples such as the surface of a heterogeneous catalyst, a phase boundary, or on a one microliter (μL) subsample within a larger liquid volume.
=== Pharmacokinetics === Methylliberine has a short half-life of only 1.5 hours compared to the 5- to 7-hour half-life of caffeine. An interaction study showed concomitant administration of both caffeine and methylliberine increases the half-life of caffeine by about 2 fold. This is likely due to inhibition of the CYP1A2 enzyme.
== Deaths == 18 January – Sir David Cox, English statistician (b. 1924) 15 March – Eugene Parker, American solar and plasma physicist (b. 1927) 20 March – Wen Shengchang, Chinese oceanographer and member of the Chinese Academy of Sciences (b. 1921) 23 March – Arthur Riggs, American geneticist (b. 1939) 27 March – Martin Pope, American physical scientist (b. 1918) 27 March – James Vaupel, American demographer and aging researcher (b. 1945) 29 March – Paul Benioff, American physicist of quantum computing (b. 1930) 30 March – Kenneth Walters, British mathematician and rheologist (b. 1934) 1 April – Gerhard J. Woeginger, Austrian mathematician. 5 April – Sidney Altman, Canadian-American molecular biologist, Nobel Prize laureate (1989). 5 April – Bjarni Tryggvason, Icelandic-born Canadian astronaut (STS-85). 5 April – Eelco Visser, Dutch computer scientist. 5 April – Leslie Young, New Zealand economist. 1 May – Ray Freeman, British chemist. 1 May – Dominique Lecourt, French philosopher. 2 May – Joseph Raz, Israeli philosopher. 4 May – Amanda Claridge, Canadian archaeologist. 7 May – Sir Paul Mellars, British archaeologist. 8 May – Harry Dornbrand, American aerospace engineer. 8 May – Zhuang Qiaosheng, Chinese geneticist and wheat breeder, member of the Chinese Academy of Sciences. 9 May – John H. Coates, Australian mathematician. 14 May – Bernard Bigot, French physicist and civil servant, director general of ITER (b. 1950) 9 June – Gordon M. Shepherd, American neuroscientist. 26 July – James Lovelock, English environmentalist (Gaia hypothesis) and futurist (b.
Sources: en.wikipedia.org
== Adverse effects == Adverse effects include hypersensitivity reactions and allergic reactions, immune system disorders, skin disorders including hives, oedema and widespread rashes. Additionally, the following adverse effects have been reported: heartburn, indigestion, tiredness, diarrhoea, constipation, loss of appetite, general malaise, dizziness, insomnia, headache, and decreased pulse rate. It does not have systemic anticholinergic side effects. Mebeverine can, on highly rare occasions, cause drug-induced acute angle closure glaucoma. In a urine drug-screening test, mebeverine can affect a false positive result for amphetamines.
The 2006 northwest Atlantic cod quota is 23,000 tons, representing half the available stocks, while the northeast Atlantic quota is 473,000 tons. Pacific cod is currently enjoying strong global demand. The 2006 total allowable catch (TAC) for the Gulf of Alaska and Aleutian Islands was 260,000 tons. In 2026, Canada increased the Northern cod quota by 55 per cent, from 38,000 tonnes to 59,000 tonnes.
Born in Belleville, Ontario, he enrolled at Trinity College at the University of Toronto at the age of 15, and studied physiology and biochemistry. He obtained a Ph.D. in biochemistry from the same university in 1916.
Sources: en.wikipedia.org
A group at the Nobel Institute for Physics in Stockholm independently discovered the element, producing an isotope later confirmed to be 250Fm (t1/2 = 30 min) by bombarding a 238U target with 16O ions, and published their work in May 1954. Nevertheless, the priority of the Berkeley team was generally recognized, and with it the prerogative to name the new element in honour of Enrico Fermi, the developer of the first artificial self-sustained nuclear reactor. Fermi was still alive when the name was proposed, but had died by the time it became official.
=== December === 6 December Scientists, for the first time, report a recently discovered area on the current planet Earth, particularly in the Puna de Atacama territory of South America, which may be similar to ancient Earth, and the related environment of the first life forms on Earth – as well as – similar to possibly hospitable conditions on the planet Mars during earlier Martian times. Google DeepMind announces its Gemini multimodal language model, which it claims has advanced "reasoning capabilities" and can outperform GPT-4 on a variety of tasks. 7 December A gene therapy based on three transcription factors, Oct4, Sox2, and Klf4 (OSK), is shown to provide sustained vision recovery in mice affected by glaucoma. Physicists report future proposed plans for the next ten years. These proposals are intended to help better understand some of the current concerns of particle physics, including challenges to the Standard Model, and involve studies primarily dealing with gravity, black holes, dark matter, dark energy, Higgs boson, muons, neutrinos, and more. Quantum entanglement of molecules is achieved for the first time. A comprehensive review of ancient carbon dioxide levels and corresponding temperatures is published by a consortium of more than 80 researchers from 16 nations. Their study finds that current levels of atmospheric carbon dioxide are the highest in at least 14 million years, much longer ago than some existing assessments indicate.
=== Cephalopods === Architeuthis dux, giant squid (2020) Euprymna scolopes, Hawaiian bobtail squid (2019) Hapalochlaena maculosa, Southern blue-ringed octopus (2020) Octopus bimaculoides, California two-spot octopus (2015) Octopus minor, common long-arm octopus (2018) Octopus vulgaris, common octopus (2019)
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.